UNSPSC 51131753: Ozagrel sodium

This classification denotes an enzyme inhibitor and antiplatelet agent C13H11N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4X5577N3ET, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, sodium salt (1:1), (2e)-, but more generally known as ozagrel sodium, which bears US NIH Compound Identifier 23663942. European Medicines Agency schedules Ozagrel sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03604MIG.

Most nations, for tariff and trade purposes, schedule ozagrel sodium under HS 29332990 and SITC 51573. As of Q4 2014, OZAGREL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)[O-].[NA+].

UNSPSC 51131753 Ozagrel sodium is a Commodity code identifying a pharmaceutical antiplatelet agent, but the recent state and local contracting activity posted under this code does not match its scope. Sourcewell, a Minnesota local government cooperative, posted RFP #061626 on May 12, 2026 to establish a contracting solution for law enforcement equipment across its participating entities — a procurement plainly unrelated to pharmaceutical products. The code shows no recent opportunities aligned with its actual commodity definition.

The mismatch between the code's pharmaceutical scope and the law enforcement equipment solicitation suggests either a data-entry error in the state or local procurement system or a temporary categorical misalignment in how Sourcewell or its participating jurisdictions tagged the opportunity. No additional state or local opportunities under UNSPSC 51131753 appear in recent posting activity. Business development professionals should verify whether ozagrel sodium purchasing actually occurs through state and local procurement channels in their target markets before investing in pursuit strategy under this code.